Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-101 in chronic antibiotic-resistant pouchitis
NL-OMON52357Phase 2Active, not recruiting
- Sponsor
- Applied Molecular Transport
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pouchitis comparing AMT-101 with Placebo (2 arms). Primary endpoints: Stool frequency response at Week 12 and Histologic healing at Week 12. Started Dec 2021; status: active, not recruiting.
02
Drugs
AMT-101
03
Conditions
pouchitis
Beyond the preview
Go deeper on NL-OMON52357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52357.